When compared to using only anti‐EGFRvIII CAR‐NK cells, the approach of employing CXCR4‐engineered anti‐EGFRvIII CAR‐NK cells has shown enhanced migration towards glioblastoma sites that produce the specific chemokine CXCL12/SDF‐1. Here, CXCL12 is linked to glioblastoma.